AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Received FDA Type 2b feedback providing greater clarity on AEON's integrated biosimilar developmen
Received FDA Type 2b feedback providing greater clarity on AEON's integrated biosimilar developmen